PHM — Pharma Mar SA Income Statement
0.000.00%
- €1.28bn
- €1.19bn
- €174.86m
Annual income statement for Pharma Mar SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 270 | 230 | 196 | 158 | 175 |
Cost of Revenue | |||||
Gross Profit | 256 | 213 | 183 | 149 | 167 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 114 | 137 | 152 | 162 | 168 |
Operating Profit | 156 | 92.4 | 44.1 | -3.83 | 6.47 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 146 | 95.1 | 43.8 | -3.62 | 12 |
Provision for Income Taxes | |||||
Net Income After Taxes | 137 | 92.9 | 49.4 | 1.14 | 26.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 137 | 92.9 | 49.4 | 1.14 | 26.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 137 | 92.9 | 49.4 | 1.14 | 26.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 7.52 | 5.12 | 2.8 | 0.067 | 1.47 |
Dividends per Share |